Predicting thrombosis risk in lung cancer patients on immune therapy
Official title: Development and Application of a Thrombosis Risk Prediction Model in Lung Cancer Patients Treated With Immune Checkpoint Inhibitors
Run by Beijing Chao Yang Hospital · NCT06950697 · Data updated 2026-11-12
This study is trying to see if certain factors can help predict the risk of blood clots in lung cancer patients receiving immune therapy.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 2400 (estimated) |
| Sponsor | Beijing Chao Yang Hospital Academic / other |
| Locations | 5 sites (Zhengzhou, Henan and 4 other locations) |
| Status | Recruiting |
| Started | January 1, 2019 |
| Main results expected | December 31, 2026 |
| Study ends | December 1, 2027 |
| Registry record updated | April 30, 2026 |
| Trial ID | NCT06950697 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include adults aged 18 and older with a confirmed diagnosis of lung cancer who have received at least one dose of a China-approved immune checkpoint inhibitor.
✕Probably not a fit
Patients who do not have lung cancer or those who have not received immune checkpoint inhibitors may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study aims to investigate the incidence and risk factors of venous and arterial thromboembolism (VTE/ATE) in lung cancer patients treated with immune checkpoint inhibitors (ICIs). Researchers will analyze the relationship between these thrombotic events and therapeutic outcomes to understand their impact on patient prognosis. By comparing characteristics and biomarkers of patients with and without ICI-associated VTE/ATE, the study seeks to identify specific biomarkers for thrombotic events. Ultimately, a risk assessment model will be developed to guide prevention and treatment strategies in clinical practice.
Why it matters
Potential benefit: If successful, this study could lead to improved risk assessment and management strategies for lung cancer patients undergoing immune therapy, potentially enhancing their treatment outcomes.
How similar studies have gone: While this study explores a specific aspect of thromboembolism in lung cancer patients treated with ICIs, similar studies have shown varying degrees of success in identifying risk factors for thrombotic events in cancer patients.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age ≥18 years * Histopathologically confirmed lung cancer diagnosis at enrollment * Received at least one dose of a China-approved lung cancer immune checkpoint inhibitor * Signed informed consent form Exclusion Criteria: * Presence of two or more primary cancers * Missing data for key variables * Inability to comply with follow-up requirements * Presence of VTE/ATE at the time of ICI initiation
Where it's running
-
The First Affiliated Hospital of Zhengzhou University
Zhengzhou, Henan, China Recruiting -
The Fourth Hospital of Inner Mongolia Autonomous Region
Hohhot, Inner Mongolia, China Recruiting -
Beijing Chaoyang Hospital, Capital Medical University
Beijing, China Recruiting -
Beijing Luhe Hospital, Capital Medical University
Beijing, China Recruiting -
China-japan Friendship Hospital
Beijing, China Recruiting
Study contacts
- Study coordinator: Yuhui Zhang
- Email: zhangyhcy@163.com
- Phone: 86+13520108369
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Aspiration thrombectomy with the Symphony or Prodigy devices
This project will try the Symphony and Prodigy aspiration thrombectomy devices to remove arterial, venous, or pulmonary blood clots in adults.
-
Evaluating DOAC levels in Chinese patients with atrial fibrillation
This study is testing how stopping blood-thinning medication for a short time affects Chinese patients with atrial fibrillation to see if it's safe for them during medical procedures.
-
ePRO in advanced lung cancer: emotional distress, brain metastasis, and symptom burden
This study tests how patients with advanced lung cancer—some with brain metastases—report emotional distress and symptoms over time using electronic questionnaires.
-
Urine VOC Test to Detect Lung Cancer in Never Smokers
A urine test that looks for volatile compounds is tested to see if it can help detect lung cancer in adults who have never smoked.
-
DoACs vs LMWH for blood flow after knee replacement
This study tests whether rivaroxaban, apixaban, or LMWH work differently to support blood flow in the legs after total knee replacement in adults.
-
SI-B036 safety test in advanced and metastatic solid tumors
This early-phase study checks whether SI-B036 is safe and tolerable in adults with advanced or metastatic solid cancers who have had prior therapy.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.